195 related articles for article (PubMed ID: 29547881)
1. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.
Savic RM; Jagannathan P; Kajubi R; Huang L; Zhang N; Were M; Kakuru A; Muhindo MK; Mwebaza N; Wallender E; Clark TD; Opira B; Kamya M; Havlir DV; Rosenthal PJ; Dorsey G; Aweeka FT
Clin Infect Dis; 2018 Sep; 67(7):1079-1088. PubMed ID: 29547881
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial.
Jagannathan P; Kakuru A; Okiring J; Muhindo MK; Natureeba P; Nakalembe M; Opira B; Olwoch P; Nankya F; Ssewanyana I; Tetteh K; Drakeley C; Beeson J; Reiling L; Clark TD; Rodriguez-Barraquer I; Greenhouse B; Wallender E; Aweeka F; Prahl M; Charlebois ED; Feeney ME; Havlir DV; Kamya MR; Dorsey G
PLoS Med; 2018 Jul; 15(7):e1002606. PubMed ID: 30016328
[TBL] [Abstract][Full Text] [Related]
3. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
[TBL] [Abstract][Full Text] [Related]
4. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.
Kajubi R; Ochieng T; Kakuru A; Jagannathan P; Nakalembe M; Ruel T; Opira B; Ochokoru H; Ategeka J; Nayebare P; Clark TD; Havlir DV; Kamya MR; Dorsey G
Lancet; 2019 Apr; 393(10179):1428-1439. PubMed ID: 30910321
[TBL] [Abstract][Full Text] [Related]
5. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.
Wallender E; Vucicevic K; Jagannathan P; Huang L; Natureeba P; Kakuru A; Muhindo M; Nakalembe M; Havlir D; Kamya M; Aweeka F; Dorsey G; Rosenthal PJ; Savic RM
J Infect Dis; 2018 Mar; 217(6):964-972. PubMed ID: 29272443
[TBL] [Abstract][Full Text] [Related]
6. Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.
Hughes E; Wallender E; Kajubi R; Jagannathan P; Ochieng T; Kakuru A; Kamya MR; Clark TD; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
Clin Infect Dis; 2022 Aug; 75(3):406-415. PubMed ID: 34864925
[TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Kakuru A; Jagannathan P; Muhindo MK; Natureeba P; Awori P; Nakalembe M; Opira B; Olwoch P; Ategeka J; Nayebare P; Clark TD; Feeney ME; Charlebois ED; Rizzuto G; Muehlenbachs A; Havlir DV; Kamya MR; Dorsey G
N Engl J Med; 2016 Mar; 374(10):928-39. PubMed ID: 26962728
[TBL] [Abstract][Full Text] [Related]
8. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial.
Desai M; Gutman J; L'lanziva A; Otieno K; Juma E; Kariuki S; Ouma P; Were V; Laserson K; Katana A; Williamson J; ter Kuile FO
Lancet; 2015 Dec; 386(10012):2507-19. PubMed ID: 26429700
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial.
González R; Nhampossa T; Mombo-Ngoma G; Mischlinger J; Esen M; Tchouatieu AM; Mendes A; Figueroa-Romero A; Zoleko-Manego R; Lell B; Lagler H; Stoeger L; Dimessa LB; El Gaaloul M; Sanz S; Méndez S; Piqueras M; Sevene E; Ramharter M; Saúte F; Menendez C;
Lancet Infect Dis; 2024 May; 24(5):476-487. PubMed ID: 38224706
[TBL] [Abstract][Full Text] [Related]
10. Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial.
Madanitsa M; Barsosio HC; Minja DTR; Mtove G; Kavishe RA; Dodd J; Saidi Q; Onyango ED; Otieno K; Wang D; Ashorn U; Hill J; Mukerebe C; Gesase S; Msemo OA; Mwapasa V; Phiri KS; Maleta K; Klein N; Magnussen P; Lusingu JPA; Kariuki S; Mosha JF; Alifrangis M; Hansson H; Schmiegelow C; Gutman JR; Chico RM; Ter Kuile FO
Lancet; 2023 Mar; 401(10381):1020-1036. PubMed ID: 36913959
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Intermittent Preventive Treatment of Malaria During Pregnancy and Placental Malaria on Infant Risk of Malaria.
Andronescu LR; Sharma A; Peterson I; Kachingwe M; Kachepa W; Liang Y; Gutman JR; Mathanga DP; Chinkhumba J; Laufer MK
J Infect Dis; 2022 Jan; 225(2):248-256. PubMed ID: 34216212
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.
Benjamin JM; Moore BR; Salman S; Page-Sharp M; Tawat S; Yadi G; Lorry L; Siba PM; Batty KT; Robinson LJ; Mueller I; Davis TM
Antimicrob Agents Chemother; 2015 Jul; 59(7):4260-71. PubMed ID: 25963981
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine.
Permala J; Tarning J; Nosten F; White NJ; Karlsson MO; Bergstrand M
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242661
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine for malaria during pregnancy: an analysis using efficacy results from Uganda and Kenya, and pooled data.
Fernandes S; Were V; Gutman J; Dorsey G; Kakuru A; Desai M; Kariuki S; Kamya MR; Ter Kuile FO; Hanson K
Lancet Glob Health; 2020 Dec; 8(12):e1512-e1523. PubMed ID: 33137287
[TBL] [Abstract][Full Text] [Related]
15. Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial.
Madanitsa M; Kalilani L; Mwapasa V; van Eijk AM; Khairallah C; Ali D; Pace C; Smedley J; Thwai KL; Levitt B; Wang D; Kang'ombe A; Faragher B; Taylor SM; Meshnick S; Ter Kuile FO
PLoS Med; 2016 Sep; 13(9):e1002124. PubMed ID: 27622558
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Intermittent Preventive Treatment With Dihydroartemisinin-Piperaqunine Against Malaria in Pregnancy in Tanzania: A Randomized Controlled Trial.
Mlugu EM; Minzi O; Kamuhabwa AAR; Aklillu E
Clin Pharmacol Ther; 2021 Dec; 110(6):1478-1489. PubMed ID: 33891721
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.
Moore BR; Benjamin JM; Tobe R; Ome-Kaius M; Yadi G; Kasian B; Kong C; Robinson LJ; Laman M; Mueller I; Rogerson S; Davis TME
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405866
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.
Barsosio HC; Madanitsa M; Ondieki ED; Dodd J; Onyango ED; Otieno K; Wang D; Hill J; Mwapasa V; Phiri KS; Maleta K; Taegtmeyer M; Kariuki S; Schmiegelow C; Gutman JR; Ter Kuile FO
Lancet; 2024 Jan; 403(10424):365-378. PubMed ID: 38224710
[TBL] [Abstract][Full Text] [Related]
19. Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.
Muhindo MK; Jagannathan P; Kakuru A; Opira B; Olwoch P; Okiring J; Nalugo N; Clark TD; Ruel T; Charlebois E; Feeney ME; Havlir DV; Dorsey G; Kamya MR
Lancet Infect Dis; 2019 Sep; 19(9):962-972. PubMed ID: 31307883
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial.
Kabuya JB; Ippolito MM; Sikalima J; Tende C; Champo D; Mwakazanga D; Young AMP; Mulenga M; Chongwe G; Manyando C
Trials; 2021 Nov; 22(1):820. PubMed ID: 34801059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
